Search | Clinical Trials Finder

Conditions: Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
Interventions: PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide; Biological · Drug
Lead sponsor: Katy Peters, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer
Interventions: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 120 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 120 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: OCPM Immunotherapeutic Vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, incomplete Freund's adjuvant, tyrosinase peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
Interventions: WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim), Montanide adjuvant; Biological · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, aldesleukin, gp100 antigen, incomplete Freund's adjuvant; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, incomplete Freund's adjuvant; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, biopsy; Biological · Procedure
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HIV Infection
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: 6MHP, Montanide ISA-51, polyICLC, Cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma, Recurrent Brain Neoplasm
Interventions: Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim; Other · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant, Magnetic Resonance Imaging, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide; Procedure · Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer
Interventions: tumor peptide vaccine; Biological
Lead sponsor: Michael Morse, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: The Immune Response Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more

Conditions: Lung Neoplasms
Interventions: P10s-PADRE vaccine; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, incomplete Freund's adjuvant, interleukin-2 gene, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51, Tetanus toxoid; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions: PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine; Biological · Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 3 Years to 39 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 13
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more

Search by objective public record fields.

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

Vaccine Therapy in Treating Patients With Melanoma

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Advanced Melanoma

Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Vaccination of Advanced-Stage Lung Cancer Patients

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Vaccination With Tetanus and KLH to Assess Immune Responses.

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma